POSB127 Cost-Comparison of HBA1C reduction with Gliclazide-Modified Release or Sitaglipltin in Patients with Uncontrolled Type 2 Diabetes after Metformin Monotherapy
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.400
https://www.valueinhealthjournal.com/article/S1098-3015(21)02195-1/fulltext
Title :
POSB127 Cost-Comparison of HBA1C reduction with Gliclazide-Modified Release or Sitaglipltin in Patients with Uncontrolled Type 2 Diabetes after Metformin Monotherapy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02195-1&doi=10.1016/j.jval.2021.11.400
First page :
Section Title :
Open access? :
No
Section Order :
11178